CAMX Stock Analysis: Camurus | ST
Biotechnology | ST, Sweden | Market Cap: 33.980m SEK | 12M Return: -14.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 73.2M
EPS Trend: 59.1%
Qual. Beats: -3
Rev. Trend: 92.0%
Qual. Beats: -3
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Camurus AB is a Swedish biopharmaceutical company founded in 1991 and headquartered in Lund, developing and commercializing treatments for severe and chronic diseases across Europe, Africa, the Middle East, North America, and Asia. Its lead commercial product, Buvidal, is a long-acting buprenorphine injection for opioid dependence and chronic pain, with the company also offering Brixadi for opioid use disorder. Like many biopharmaceutical firms, Camurus operates a pipeline-driven model in which current product revenues support investment in a broad set of clinical-stage programs.
The pipeline spans oncology, endocrine, metabolic, cardiovascular, and rare genetic disorders, with candidates ranging from Phase I through completed Phase III trials, including CAM2029 for acromegaly and gastroenteropancreatic neuroendocrine tumors and CAM4072 for genetic obesity disorders. Camurus also pursues a partnership-driven business model, collaborating with Braeburn Pharmaceuticals, Rhythm Pharmaceuticals, Gubra, NewBridge Pharmaceuticals, and Eli Lilly. Several of these collaborations leverage the companys proprietary FluidCrystal technology, a lipid-based depot delivery platform used to formulate long-acting injectable therapies.
- Brixadi US launch accelerates opioid dependence treatment revenue growth
- CAM2029 acromegaly approval expands specialty endocrinology franchise
- Eli Lilly partnership advances long-acting incretin obesity pipeline
| Net Income: 682.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 7.09 > 1.0 |
| NWC/Revenue: 188.2% < 20% (prev 161.5%; Δ 26.70% < -1%) |
| CFO/TA 0.19 > 3% & CFO 953.8m > Net Income 682.1m |
| Net Debt (-3.77b) to EBITDA (890.6m): -4.23 < 3 |
| Current Ratio: 11.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.8m) vs 12m ago -0.15% < -2% |
| Gross Margin: 92.53% > 18% (prev 93.04%; Δ -0.51% > 0.5%) |
| Asset Turnover: 50.19% > 50% (prev 51.29%; Δ -1.11% > 0%) |
| Interest Coverage Ratio: 146.6 > 6 (EBIT TTM 864.4m / Interest Expense TTM 5.90m) |
| A: 0.85 (Total Current Assets 4.62b - Total Current Liabilities 398.9m) / Total Assets 4.96b |
| B: 0.15 (Retained Earnings 754.3m / Total Assets 4.96b) |
| C: 0.19 (EBIT TTM 864.4m / Avg Total Assets 4.46b) |
| D: 8.25 (Book Value of Equity 4.42b / Total Liabilities 535.9m) |
| Altman-Z'' = 16.04 = AAA |
| DSRI: 0.85 (Receivables 622.3m/665.3m, Revenue 2.24b/2.04b) |
| GMI: 1.01 (GM 93.04% / 92.53%) |
| AQI: 0.17 (AQ_t 0.00 / AQ_t-1 0.03) |
| SGI: 1.10 (Revenue 2.24b / 2.04b) |
| TATA: -0.05 (NI 682.1m - CFO 953.8m) / TA 4.96b) |
| Beneish M = -3.57 (Cap -4..+1) = AAA |
As of July 08, 2026, the stock is trading at SEK 578.00 with a total of 73,920 shares traded. Over the past week, the price has changed by +2.21%, over one month by +7.14%, over three months by +22.46% and over the past year by -14.37%.
Current recommended Stop Loss: 552.80 (which is 4.4% or 1.2 ATR below the current price).
Camurus has no consensus analysts rating.
P/E Trailing = 50.2199
P/E Forward = 45.4545
P/S = 15.1686
P/B = 7.6827
Revenue TTM = 2.24b SEK
EBIT TTM = 864.4m SEK
EBITDA TTM = 890.6m SEK
Long Term Debt = 85.9m SEK (from longTermDebtTotal, last fiscal year)
Short Term Debt = 21.4m SEK (from shortTermDebt, last quarter)
Debt = 110.1m SEK (from shortLongTermDebtTotal, last quarter) (leases 110.1m already included)
Net Debt = -3.77b SEK (calculated: Debt 110.1m - CCE 3.88b)
Enterprise Value = 30.2b SEK (34.0b + Debt 110.1m - CCE 3.88b)
Interest Coverage Ratio = 146.6 (Ebit TTM 864.4m / Interest Expense TTM 5.90m)
EV/FCF = 37.27x (Enterprise Value 30.2b / FCF TTM 810.6m)
FCF Yield = 2.68% (FCF TTM 810.6m / Enterprise Value 30.2b)
FCF Margin = 36.19% (FCF TTM 810.6m / Revenue TTM 2.24b)
Net Margin = 30.45% (Net Income TTM 682.1m / Revenue TTM 2.24b)
Gross Margin = 92.53% ((Revenue TTM 2.24b - Cost of Revenue TTM 167.3m) / Revenue TTM)
Gross Margin QoQ = 91.74% (prev 92.17%)
Tobins Q-Ratio = 6.09 (Enterprise Value 30.2b / Total Assets 4.96b)
Interest Expense / Debt = 5.36% (Interest Expense 5.90m / Debt 110.1m)
Taxrate = 20.96% (180.9m / 863.0m)
NOPAT = 683.2m (EBIT 864.4m * (1 - 20.96%))
Current Ratio = 11.57 (Total Current Assets 4.62b / Total Current Liabilities 398.9m)
Debt / Equity = 0.02 (Debt 110.1m / totalStockholderEquity, last quarter 4.42b)
Debt / EBITDA = -4.23 (Net Debt -3.77b / EBITDA 890.6m)
Debt / FCF = -4.65 (Net Debt -3.77b / FCF TTM 810.6m)
Total Stockholder Equity = 4.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.28% (Net Income 682.1m / Total Assets 4.96b)
RoE = 16.39% (Net Income TTM 682.1m / Total Stockholder Equity 4.16b)
RoCE = 20.35% (EBIT 864.4m / Capital Employed (Equity 4.16b + L.T.Debt 85.9m))
RoIC = 15.29% (NOPAT 683.2m / Invested Capital 4.47b)
WACC = 8.70% (E(34.0b)/V(34.1b) * Re(8.71%) + D(110.1m)/V(34.1b) * Rd(5.36%) * (1-Tc(0.21)))
Discount Rate = 8.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 68.89 | Cagr: 3.35%
[DCF] Terminal Value 76.86% ; FCFF base≈633.3m ; Y1≈726.0m ; Y5≈1.07b
[DCF] Fair Price = 318.0 (EV 15.2b - Net Debt -3.77b = Equity 18.9b / Shares 59.5m; r=8.70% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 59.06 | EPS CAGR: 28.83% | SUE: -1.35 | # QB: -3
Revenue Correlation: 91.99 | Revenue CAGR: 18.04% | SUE: -1.53 | # QB: -3
EPS current Quarter (2026-06-30): EPS=3.11 | Chg30d=-18.05% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=3.85 | Chg30d=+0.73% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=13.59 | Chg30d=+3.48% | Revisions=-25% | GrowthEPS=+10.8% | GrowthRev=+24.0%
EPS next Year (2027-12-31): EPS=26.97 | Chg30d=-1.18% | Revisions=+0% | GrowthEPS=+98.5% | GrowthRev=+46.8%
[Analyst] Revisions Ratio: -17% (up=1, down=2)